The company is currently conducting clinical trials to seek FDA approval for a new treatment aimed at sphincter-related disorders like gastroesophageal reflux disease (GERD) and urinary urge incontinence. EndoStim's microstimulator technology restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle, providing long-term reflux control. This approach allows patients to reduce or avoid the typical gastrointestinal side effects associated with traditional anti-reflux surgery. With a focus on developing and commercializing treatments for gastroesophageal reflux disease, EndoStim aims to provide patients with an effective and minimally invasive alternative to existing options.